Is Ruxolitinib included in medical insurance?

Ruxolitinib tablets The original drug has been launched in China and is included in the scope of Class B medical insurance, but it is limited to patients who meet the indications, including limited to intermediate-risk or high-risk primary myelofibrosis (PMF), myelofibrosis secondary to polycythemia vera (PPV-MF) or myelofibrosis secondary to essential thrombocythemia (PET-MF), the price of each box of 5mg*60 tablets may be around RMB 3,000.

Ruxolitinib tabletsThis kinase inhibitor is suitable for the treatment of patients with moderate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. It is also suitable for patients with polycythemia vera who have a poor response to or intolerance to hydroxyurea, and is also suitable for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and chronic graft-versus-host disease (cGVHD) after failure of 1 or 2 systemic therapies. Patients should have a complete blood count (CBC) and platelet count before starting treatment, Weeks 2-4, until the dose is stable, and then continue using the drug as clinically indicated.

The Turkish version of ruxolitinib tablets sold overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.